Hospitalisation for RSV infection · children (0 to 24 months)
Palivizumab leads to lower hospitalisation due to RSV infection compared with placebo, no intervention or standard care (high certainty).
1 finding from 1 review
All‐cause mortality · children (0 to 24 months)
Palivizumab showed no clear difference in mortality compared with placebo, no intervention or standard care (moderate certainty).
1 finding from 1 review
Adverse events · children (0 to 24 months)
Palivizumab showed no clear difference in adverse events compared with placebo, no intervention or standard care (moderate certainty).
1 finding from 1 review
Hospitalisation due to respiratory‐related illness · children (0 to 24 months)
Palivizumab probably leads to lower hospitalisation due to respiratory‐related illness compared with placebo, no intervention or standard care (moderate certainty).
1 finding from 1 review
RSV infection · children (0 to 24 months)
Palivizumab may leads to lower RSV infection compared with placebo, no intervention or standard care (low certainty).
1 finding from 1 review
Number of wheezing days · children (0 to 24 months)
Palivizumab leads to lower number of wheezing days compared with placebo, no intervention or standard care (high certainty).
1 finding from 1 review
Hospitalisation for RSV infection · patients at high risk of severe respiratory syncytial virus infection
Palivizumab leads to lower hospitalisation for RSV infection compared with placebo (high certainty).
1 finding from 1 review
Total RSV hospital days per 100 children · patients at high risk of severe respiratory syncytial virus infection
1 finding from 1 review
Incidence of admissions to the ICU · patients at high risk of severe respiratory syncytial virus infection
Palivizumab showed no clear difference in admission to ICU compared with motavizumab (moderate certainty).
1 finding from 1 review
Mechanical ventilation for RSV infection · patients at high risk of severe respiratory syncytial virus infection
Palivizumab leads to higher mechanical ventilation for RSV infection compared with motavizumab (high certainty).
1 finding from 1 review
Supplemental oxygen therapy for RSV infection · patients at high risk of severe respiratory syncytial virus infection
Palivizumab showed no clear difference in supplemental oxygen therapy for RSV infection compared with motavizumab (moderate certainty).
1 finding from 1 review
Number of children reporting any SAE · patients at high risk of severe respiratory syncytial virus infection
Palivizumab showed no clear difference in number of children reporting any SAE compared with motavizumab (high certainty).
1 finding from 1 review
All‐cause mortality · patients at high risk of severe respiratory syncytial virus infection
Palivizumab showed no clear difference in all‐cause mortality compared with placebo (moderate certainty).
1 finding from 1 review
Total RSV hospital days per 100 children · patients at high risk of severe respiratory syncytial virus infection
1 finding from 1 review
Incidence of admissions to the ICU · patients at high risk of severe respiratory syncytial virus infection
Palivizumab leads to lower admission to ICU compared with placebo (high certainty).
1 finding from 1 review
Mechanical ventilation for RSV infection · patients at high risk of severe respiratory syncytial virus infection
It is very uncertain whether palivizumab changes mechanical ventilation for RSV infection compared with placebo (very low certainty).
1 finding from 1 review
Supplemental oxygen therapy for RSV infection · patients at high risk of severe respiratory syncytial virus infection
1 finding from 1 review
Number of children reporting any SAE · patients at high risk of severe respiratory syncytial virus infection
Palivizumab leads to lower number of children reporting any SAE compared with placebo (high certainty).
1 finding from 1 review
Hospitalisation for RSV infection · patients at high risk of severe respiratory syncytial virus infection
Palivizumab showed no clear difference in hospitalisation for RSV infection compared with motavizumab (moderate certainty).
1 finding from 1 review
All‐cause mortality · patients at high risk of severe respiratory syncytial virus infection
Palivizumab showed no clear difference in all‐cause mortality compared with motavizumab (moderate certainty).
1 finding from 1 review